Background Dihydropyridine calcium channel blockers (DHP-CCB) are widely used in heart failure (HF), despite the lack of data regarding their safety, especially in patients with reduced ejection fraction (HFrEF). We aimed to evaluate DHP-CCB prescription trends over time, their association with GDMT uptake and related outcomes across the spectrum of EF. Methods We studied outpatients with chronic HF prospectively enrolled in the nationwide observational IN-HF registry from 1998 to 2022. We used Cox regression methods to analyze all-cause mortality and cardiovascular hospitalization at 1-year according to DHP-CCB exposure, applying inverse probability of treatment weighting (IPTW). Results We included 15785 outpatients. 10829 (69 %) had HFrEF, and 4956(31 %) an EF>40 %. Median age was 69; 26.6 % were females. Overall, 1458 patients (9.1 %) received a DHP-CCB. DHP-CCB administration was twice as prevalent in patients with an EF>40 % than in those with HFrEF (13.9 %¦vs 7.1 %, respectively p<0.001). DHP-CCB prescription rates increased over time (p<0.001). Patients who received DHP-CCB were older, more comorbid, had a higher EF, and were less frequently prescribed GDMT than those who were not on DHP-CCB. After multivariable adjustment, using IPTW analysis, DHP-CCB prescription was associated with a higher risk of the outcome in the overall cohort (HR 1.11, 95 % CI 1.09-1.12, p<0.001), among HFrEF patients (HR 1.14, 95 % CI 1.12-1.16, p<0.001), and those with EF>40 % (HR 1.07, 95 % CI 1.04-1.10, p<0.001). Conclusion DHP-CCB use in HFrEF was associated with less GDMT prescription and worse outcomes. Additionally, DHP-CCB safety needs to be further explored in HFmrEF/HFpEF.
Effects of calcium channel blockers on GDMT prescription and outcomes according to ejection fraction: IN-HF real world data / Gori M., Fazzini L., Meessen J., Limonta R., Carigi S., Di Nora C., Manca P., Tinti D., Gori M., Palmieri V., De Gennaro L., Nora C.D., Matassini M.V., Bianco M., Tinti M.D., Rizzello V., De Maria R., Maggioni A.P., Orso F., Gorini M., et al.. - In: EUROPEAN JOURNAL OF INTERNAL MEDICINE. - ISSN 0953-6205. - ELETTRONICO. - 144:(2026), pp. 106589.0-106589.0. [10.1016/j.ejim.2025.106589]
Effects of calcium channel blockers on GDMT prescription and outcomes according to ejection fraction: IN-HF real world data
Maggioni A. P.;Navazio A.;Oliva F. G.;Frigerio M.;Mortara A.;Urbinati S.;Milli M.;Ungar A.;Murrone A.;Battistoni I.;Perna G. P.;Gabrielli D.;Francese G. M.;Gulizia M. M.;
2026
Abstract
Background Dihydropyridine calcium channel blockers (DHP-CCB) are widely used in heart failure (HF), despite the lack of data regarding their safety, especially in patients with reduced ejection fraction (HFrEF). We aimed to evaluate DHP-CCB prescription trends over time, their association with GDMT uptake and related outcomes across the spectrum of EF. Methods We studied outpatients with chronic HF prospectively enrolled in the nationwide observational IN-HF registry from 1998 to 2022. We used Cox regression methods to analyze all-cause mortality and cardiovascular hospitalization at 1-year according to DHP-CCB exposure, applying inverse probability of treatment weighting (IPTW). Results We included 15785 outpatients. 10829 (69 %) had HFrEF, and 4956(31 %) an EF>40 %. Median age was 69; 26.6 % were females. Overall, 1458 patients (9.1 %) received a DHP-CCB. DHP-CCB administration was twice as prevalent in patients with an EF>40 % than in those with HFrEF (13.9 %¦vs 7.1 %, respectively p<0.001). DHP-CCB prescription rates increased over time (p<0.001). Patients who received DHP-CCB were older, more comorbid, had a higher EF, and were less frequently prescribed GDMT than those who were not on DHP-CCB. After multivariable adjustment, using IPTW analysis, DHP-CCB prescription was associated with a higher risk of the outcome in the overall cohort (HR 1.11, 95 % CI 1.09-1.12, p<0.001), among HFrEF patients (HR 1.14, 95 % CI 1.12-1.16, p<0.001), and those with EF>40 % (HR 1.07, 95 % CI 1.04-1.10, p<0.001). Conclusion DHP-CCB use in HFrEF was associated with less GDMT prescription and worse outcomes. Additionally, DHP-CCB safety needs to be further explored in HFmrEF/HFpEF.| File | Dimensione | Formato | |
|---|---|---|---|
|
Effects of calcium channel blockers on GDMT prescription.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
878.29 kB
Formato
Adobe PDF
|
878.29 kB | Adobe PDF | Richiedi una copia all'autore |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



